Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing

Genetics in Medicine

Volumn 16, Issue 11, 2014, Pages 846-853

  Aspinwall, Lisa G ^a   Taber, Jennifer M ^a   Kohlmann, Wendy ^b   Leaf, Samantha L ^a   Leachman, Sancy A ^c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

CDKN2A p16; genetic testing; melanoma prevention; sun protection; sunburn

Indexed keywords

SUNSCREEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; MALE; MELANOMA; MOTIVATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PROTECTIVE CLOTHING; RISK REDUCTION; SELF REPORT; SUN EXPOSURE; SUNBURN; ULTRAVIOLET RADIATION; ADVERSE EFFECTS; ENVIRONMENTAL EXPOSURE; GENETICS; MIDDLE AGED; PEDIGREE; PREVENTION AND CONTROL; PSYCHOLOGY; SKIN NEOPLASMS; SUNLIGHT;

ADULT; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC COUNSELING; GENETIC TESTING; HUMANS; MALE; MELANOMA; MIDDLE AGED; PATIENT COMPLIANCE; PEDIGREE; SKIN NEOPLASMS; SUNLIGHT; SUNSCREENING AGENTS;

EID: 84908879271     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2014.37     Document Type: Article

References (33)

1. Botkin JR, Smith KR, Croyle RT, et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 2003;118A:201-209.
2. Aspinwall LG, Taber JM, Kohlmann W, Leachman SA. Psychological aspects of hereditary cancer risk counseling and genetic testing. In: Carr BI, Steel J (eds). Psychological Aspects of Cancer: A Guide to Emotional and Psychological Consequences of Cancer, Their Causes and Their Management. Springer: New York, 2013:31-64.
3. McBride CM, Bowen D, Brody LC, et al. Future health applications of genomics: priorities for communication, behavioral, and social sciences research. Am J Prev Med 2010;38:556-565.
4. Marteau TM, French DP, Griffin SJ, et al. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database Syst Rev 2010;10:CD007275.
5. Collins FS, Green ED, Guttmacher AE, Guyer MS; US National Human Genome Research Institute. A vision for the future of genomics research. Nature 2003;422:835-847.
6. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007;9:665-674.
7. Bishop DT, Demenais F, Goldstein AM, et al.; Melanoma Genetics Consortium. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.
8. Begg CB, Orlow I, Hummer AJ, et al.; Genes Environment and Melanoma Study Group. Lifetime risk of melanoma in CDKN2A mutation carriers in a populationbased sample. J Natl Cancer Inst 2005;97:1507-1515.
9. Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009;61:677.e1-677.14.
10. Kefford R, Bishop JN, Tucker M, et al.; Melanoma Genetics Consortium. Genetic testing for melanoma. Lancet Oncol 2002;3:653-654.
11. Kefford RF, Mann GJ. Is there a role for genetic testing in patients with melanoma? Curr Opin Oncol 2003;15:157-161.
12. Aspinwall LG, Leaf SL, Kohlmann W, Dola ER, Leachman SA. Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. J Am Acad Dermatol 2009;60:745-757.
13. Bergenmar M, Brandberg Y. Sunbathing and sun-protection behaviors and attitudes of young Swedish adults with hereditary risk for malignant melanoma. Cancer Nurs 2001;24:341-350.
14. Brandberg Y, Jonell R, Broberg M, Sjdn PO, Rosdahl I. Sun-related behaviour in individuals with dysplastic naevus syndrome. Acta Derm Venereol 1996;76:381-384.
15. Kasparian NA, Meiser B, Butow PN, Job RF, Mann GJ. Better the devil you know? High-risk individuals anticipated psychological responses to genetic testing for melanoma susceptibility. J Genet Couns 2006;15:433-447.
16. Kasparian NA, Meiser B, Butow PN, Soames Job RF, Mann GJ. Anticipated uptake of genetic testing for familial melanoma in an Australian sample: An exploratory study. Psychooncology 2007;16:69-78.
17. Kasparian NA, Meiser B, Butow PN, Simpson JM, Mann GJ. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med 2009;11:265-278.
18. Brnstrm R, Kasparian NA, Affleck P, et al. Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma. Eur J Cancer 2012;48:3052-3062.
19. Taber JM, Aspinwall LG, Kohlmann W, Dow R, Leachman SA. Parental preferences for CDKN2A/p16 testing of minors. Genet Med 2010;12:823-838.
20. Christensen KD, Roberts JS, Shalowitz DI, et al. Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers. Cancer Epidemiol Biomarkers Prev 2011;20:522-529.
21. Glanz K, Volpicelli K, Kanetsky PA, et al. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol Biomarkers Prev 2013;22:607-614.
22. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992;258:1148-1152.
23. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-26.
24. Florell SR, Boucher KM, Garibotti G, et al. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol 2005;23:7168-7177.
25. Aspinwall LG, Leaf SL, Dola ER, Kohlmann W, Leachman SA. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in highrisk melanoma families. Cancer Epidemiol Biomarkers Prev 2008;17:1510-1519.
26. Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, Leachman SA. Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later. Cancer Epidemiol Biomarkers Prev 2013;22:1687-1697.
27. Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, Leachman SA. Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome. Psychooncology 2013;22:276-289.
28. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005;41:45-60.
29. Steffen AD, Glanz K, Wilkens LR. Identifying latent classes of adults at risk for skin cancer based on constitutional risk and sun protection behavior. Cancer Epidemiol Biomarkers Prev 2007;16:1422-1427.
30. GenoMEL the Melanoma Genetics Consortium. Genetic Counselling and Testing for Hereditary Melanoma. 2011. http://www.genomel.org/genetic-counselling/. Accessed 14 March 2014.
31. Albada A, Ausems MG, Bensing JM, van Dulmen S. Tailored information about cancer risk and screening: a systematic review. Patient Educ Couns 2009;77:155-171.
32. Glanz K, Mayer JA. Reducing ultraviolet radiation exposure to prevent skin cancer: methodology and measurement. Am J Prev Med 2005;29: 131-142.
33. Stump TK, Aspinwall LG, Leachman SA, Taber JM, Edwards R. Protectionadjusted length of exposure (PALE): a new self-report measure of UVR exposure that captures multiple modalities of photoprotection. June 2013: Paper presented at the annual meeting of the Melanoma Genetics Consortium, Philadelphia, PA.